Passage Bio and Remix Therapeutics Announce Merger Agreement

▤ Summary

Passage Bio and Remix Therapeutics have agreed to merge in an all-stock transaction, with the combined company expected to operate under the Remix Therapeutics name and list on Nasdaq as RMTX. Remix also secured a concurrent oversubscribed private placement of about $100 million that should extend runway into 2028. The combined company will keep advancing REM-422, an oral mRNA degrader targeting MYB, through Phase 1/2 studies in ACC, AML, and HR-MDS. The deal has been approved by both boards and is expected to close in the fourth quarter of 2026, subject to stockholder and regulatory approvals.

▦ Linked Companies